Full CoverageSecond patient death reported with gene therapy for muscular dystrophy
By Matthew Perrone
All coverage
Amid close calls and safety concerns, Southwest adds runway cockpit warnings to almost all of its jets
By Max Knoblauch
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
By Jef Akst, Heather McKenzie & Annalee Armstrong
Second Patient Death After Gene Therapy: Implications For The Future
By William A. Haseltine
Second Teenage Boy Dies From Liver Failure After Sarepta Gene Therapy Treatment
By Naomi Kresge, Gerry Smith & Damian Garde
Elevidys halted in nonambulatory DMD after second death reported
By Marisa Wexler
Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy
By Josh Nathan-kazis & Elsa Ohlen
Sarepta Stops Stop Shipments of Muscular Dystrophy Gene Therapy After Second Patient Death
By Frank Vinluan
Second DMD Patient Dies After Treatment with Sarepta Gene Therapy
By Alex Philippidis
Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients
By Angus Liu
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
By Avi Kapoor
SRPT FRAUD ALERT: Sarepta Therapeutics, Inc. Investors are
By Bleichmar Fonti
SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that
By Bleichmar Fonti
What’s next for Sarepta Therapeutics with gene therapy under fire?
By Adam Feuerstein
Following second patient death, Duchenne muscular dystrophy families deserve answers about Elevidys
By Christine Mcsherry